Tests KIN-2787 in adults with BRAF or NRAS mutated solid tumors
Tests the drug KIN-2787, alone or with binimetinib, in adults with advanced tumors.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Key facts
- Where
- Heidelberg, Perth, Southport, Waratah, and Wollstonecraft, AustraliaSee the 5 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an advanced or metastatic solid tumor that has a known BRAF change, or a melanoma with an NRAS mutation.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Metastatic or advanced solid tumor, with disease that can be measured or evaluated by RECIST v1.1 scans. ECOG performance status 0-1.
- Earlier treatment
- In the dose expansion part (Part B), people cannot have had earlier BRAF, MEK or MAPK inhibitor treatment.
- Biomarker or test result
- Known BRAF Class I, Class II or Class III alteration, or melanoma with an NRAS mutation, confirmed by earlier genetic testing of tumor tissue or ctDNA.
Main reasons for not taking part
- Cannot swallow, keep down or absorb oral medicines
- Gut disease that stops oral medicine, or uncontrolled inflammatory gut disease
- Active, uncontrolled bacterial, fungal or viral infection
- Positive or suspected SARS-CoV2 infection
- Pregnant, or breastfeeding
Read by machine on 12 November 2026.
Where in Australia
- Austin HealthHeidelberg, AustraliaContact: Damien Kee, MDTaking people
- Linear Clinical ResearchPerth, AustraliaContact: Michael Millward, ProfessorTaking people
- Tasman Health CareSouthport, AustraliaContact: Andrew Hill, MDTaking people
- Calvary Mater Hospital NewcastleWaratah, AustraliaContact: Emily MunnTaking people
- Melanoma Institute AustraliaWollstonecraft, AustraliaContact: Florence ClampettTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Pierre Fabre Medicament
- Trial code
- NCT04913285
- Record updated
- 2 September 2026
- Original description
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.Read full original descriptionShow less
A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
Inclusion: Provide written informed consent prior to initiation of any study-specific procedures; Metastatic or advanced stage solid tumor; Known BRAF Class I, Class II, or Class III alteration or melanoma with an NRAS mutation as confirmed by previous genomic analysis of tumor tissue or ctDNA; Measurable (Part A and B) or evaluable (Part A only) disease by RECIST v1.1; ECOG performance status 0-1; Adequate organ function, as measured by laboratory values (criteria listed in protocol); Able to swallow, retain, and absorb oral medications.
Exclusion: Known participants who have received local therapy with either surgery and/or radiation therapy (participants with asymptomatic untreated brain metastasis may be eligible if met with certain criteria); In Part B Dose Expansion, previous treatment with any approved or in-development small molecule BRAF-, MEK-, or MAPK-directed inhibitor therapy; Participants with any other active treated malignancy within 3 years prior to enrollment; Complete inclusion and exclusion criteria are listed in the clinical study protocol; GI tract disease causing an inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, or uncontrolled inflammatory GI disease; Active, uncontrolled bacterial, fungal, or viral infection; Participant with a positive test result for SARS-CoV2 infection, is known to have asymptomatic infection or is suspected of having SARS-CoV2, is excluded; Women who are lactating or breastfeeding, or pregnant.